Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment-Reference-Cited by-同舟云学术

Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment

Published:2022-01 Issue: Volume:Volume 16 Page:123-135
ISSN:1177-889X
Container-title:Patient Preference and Adherence
language:en
Short-container-title:PPA

Author:

Yong Candice,Cambron-Mellott M Janelle^ORCID,Seal Brian,Will Oliver^ORCID,Maculaitis Martine C,Clapp Kelly,Mulvihill Emily,Cotarla Ion,Mehra Ranee^ORCID

Publisher

Informa UK Limited

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Social Sciences (miscellaneous),Medicine (miscellaneous)

Reference48 articles.

1. Surveillance Epidemiology and End Results (SEER) Program. Cancer Stat Facts: Common Cancer Sites. National Cancer Institute; 2020.

2. American Cancer Society. What is Lung Cancer?; 2019.

3. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

4. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

5. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?;CLIN LUNG CANCER;2024

2. Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?;Clinical Lung Cancer;2024-09

3. Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers;Pulmonary Therapy;2023-06-13

4. Mapping the experiences of people with advanced cancer across multiple cancer types—a scoping review;Journal of Cancer Survivorship;2022-09-30